Ivermectin: does P-glycoprotein play a role in neurotoxicity?
© BioMed Central Ltd 2003
Published: 24 October 2003
Skip to main content
Volume 2 Supplement 1
© BioMed Central Ltd 2003
Published: 24 October 2003
The macrocyclic lactone ivermectin (Mectizan®) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. In areas co-endemic for Onchocerciasis and Loa loa, serious adverse reactions have been observed in patients with apparently high microfilaria counts of Loa loa. Recent findings suggest that the severe central nervous system side effects seen in various vertebrates following ivermectin treatment may be due to an absence of, or functional deficiency in P-glycoprotein. P-glycoprotein is expressed in the apical membrane of brain capillary epithelial cells and is responsible for limiting the brain penetration of a range of compounds. Toxicity of ivermectin in some collie dogs may be explained by a 4-bp deletion mutation of the mdr1 gene resulting in a frame shift, generating stop codons that prematurely terminate synthesis of P-glycoprotein. Additionally, sub-populations of CF-1 identified as expressing reduced levels of P-glycoprotein exhibit increased toxicity to substrates of this transporter. Furthermore, while the traditional view of drug-drug interactions is alteration in drug clearance mediated through a change in hepatic drug metabolism, some of these changes may arise through competition for binding sites on P-glycoprotein in the blood-brain barrier, resulting in reduced extracellular efflux and enhanced CNS toxicity. In conclusion, P-glycoprotein is an integral component of the human blood brain barrier and plays a central role in limiting drug uptake into the brain. Altered expression or function of p-glycoprotein could conceivably allow elevation of brain concentrations of ivermectin and produce severe neurotoxicity. This might arise through a genetic polymorphism in p-glycoprotein or co-administration of ivermectin with a drug or foodstuff that might inhibit this efflux transporter.
Although clinical and veterinary usage of the broad-spectrum anthelmintic agent ivermectin has generally been free of serious adverse events since 1991, a number of clinical cases with and without neurological manifestations, including coma lasting 2–3 days, have been reported after ivermectin treatment of individuals infected with Onchocerca volvulus who also had concomitant Loa loa infection with a high levels of microfilariae, typically > 30,000 microfilariae /ml of blood [1, 2]. Although a cause and effect relationship has yet to be established, it is advised that individuals who warrant treatment with ivermectin for any reason and have had significant exposure to Loa loa-endemic areas of West and Central Africa, pre-treatment assessment for loaiasis and careful post-treatment follow-up should be implemented. The aim of this brief review is to assess whether any of these events could be attributed to the pharmacology of ivermectin, notably its affinity for the P-glycoprotein drug transporter, which might serve to reduce oral bioavailability of ivermectin and prevent its uptake into the brain, thereby preventing potentially fatal neurotoxicity.
The principal toxicological effects of ivermectin seen in rats are ataxia, ptosis and decreased activity, and in dogs are mydriasis, tremors, ataxia and anorexia  with enhanced sensitivity in infant rats that have a poorly developed blood brain barrier (with regard to their deficiency in p-glycoprotein), and show higher brain plasma drug concentration ratios than adult rats. During the development of Mectizan® two reports, one from the veterinary use of ivermectin and another from a pre-clinical toxicology study, influenced the clinical development of Mectizan® such that a more conservative approach was taken . First, it was noticed that a sub-population of collie dogs was remarkably sensitive to ivermectin-induced neurotoxicity . This occurs at doses that are 1/200th of the dose required to cause toxicity in other dogs. Neurological manifestations of ivermectin in susceptible dogs include, hypersalivation, ataxia, blindness, coma, respiratory compromise, and death. It is now known that such ivermectin-sensitive collies exhibit a 4-bp deletion mutation of the mdr1 gene that results in a frame shift, generating several stop codons that prematurely terminate synthesis of P-glycoprotein. Dogs that are homozygous for the mutation display the ivermectin sensitive phenotype, whereas those homozygous normal or heterozygous show no increased sensitivity to ivermectin . Second, sub populations of CF-1 mice were identified as expressing reduced levels of P-glycoprotein, including a population that does not produce P-glycoprotein, identified as (-/-) . Animals with the wild type (+/+) or deficient genotypes differ markedly in their sensitivity to ivermectin neurotoxicity and teratology, attributable to differential accumulation of ivermectin in brain and foetus. CF1 p-glycoprotein deficient mice are phenoptypically identical to mdr1a and mdr1b knockout strains established in the laboratory . Using such strains, differences in pharmacokinetics and tissue distribution, particularly accumulation in the brain, of several substances can be demonstrated when compared with p-glycoprotein wild type mice [29, 30]. These authors clearly established the mdr1a transporter as central to limiting the oral bioavailability and brain uptake of these agents. Studies with ivermectin and the p-glycoprotein substrate cyclosporin A in CF-1 mice demonstrated enhanced absorption of ivermectin and cyclosporin A in the (-/-) strain although there were no differences in the intravenous pharmacokinetics of either drug. Hepatic drug metabolising capacity of (-/-) and (+/+) animals was similar. Concentrations of [3H]-ivermectin and [3H]-cyclosporin A were always higher in the brains of (-/-) mice after oral or intravenous administration but liver concentrations were identical to wild-type mice. These findings clearly demonstrate that changes in ivermectin disposition observed in the (-/-) mice arise through a deficiency in p-glycoprotein rather than any alteration in drug metabolism .
Drug-drug interactions of clinical importance can occur when the pharmacology of a drug is altered by co-administration of another agent. The question of drug-drug interactions among anthelmintics is yet to be answered satisfactorily. This is an important issue, since combination chemotherapy is becoming more widespread as resistance to antiparasitic agents increases. For example albendazole and ivermectin are co-administered in programmes to eliminate lymphatic filariasis . Experiments in human liver microsomes and recombinant enzyme systems have shown that ivermectin and albendazole are both substrates of cytochrome P450 (CYP) 3A4, the most widely distributed human P-450, which is expressed both in the liver and small intestine [32, 33]. We have shown that albendazole is converted to albendazole sulphoxide, the major plasma metabolite in man, by microsomes prepared from human intestinal tissue . There is, therefore, the potential for drug-drug interactions at each of these sites through competition for drug metabolising enzymes. The traditional view is that drug-drug interactions are a result of alterations in drug clearance mediated through a change in hepatic drug metabolism. However, it is becoming clear that some of these changes may arise through competition for binding sites on transport proteins. Fluorescent-labelled ivermectin (BODIPY-ivermectin) is extruded out of brain capillaries by a concentrative mechanism and this export process is reduced by substrates of p-glycoprotein without any change in drug uptake . Moreover, transport of BODIPY-ivermectin is restricted to p-glycoprotein, as it is unaffected by specific inhibitors of related transport proteins and it interacts specifically with p-glycoprotein in functional kidney tubules . These findings suggest that other P-glycoprotein substrates could compete with ivermectin at this site, resulting in reduced extracellular efflux and enhanced CNS toxicity. Such compounds include cyclosporin and HIV protease inhibitors [37, 38]. Increased ivermectin concentrations accompanied by enhanced neurotoxicity of ivermectin in mice has already been demonstrated in the presence of cyclosporin . While an interaction between ivermectin and albendazole could be postulated on the basis of these drugs being co substrates of CY3A4, it is not established that there could be an interaction at the level of p-glycoprotein. Although ivermectin is undeniably a substrate for P-glycoprotein, there is conflicting evidence for albendazole. Intestinal metabolism and secretion of albendazole sulphoxide into the intestinal lumen has been demonstrated and p-glycoprotein is reported to be involved in modulating resistance to albendazole in helminths [40, 41]. However, experiments in Caco-2 cells failed to identify albendazole as a p-glycoprotein substrate or an inhibitor of p-glycoprotein mediated transport of digoxin , suggesting that a combination of the two drugs would not produce an adverse drug reaction based upon an interaction with p-glycoprotein. Albendazole sulphoxide or sulphone were not investigated.
P-glycoprotein is an integral component of the human blood brain barrier and plays a central role in limiting drug uptake into the brain. Altered expression or function of p-glycoprotein could conceivably allow elevation of brain concentrations of ivermectin and produce severe neurotoxicity. This might arise through a genetic polymorphism in p-glycoprotein or co-administration of ivermectin with a drug or foodstuff that might inhibit this efflux transporter. There are relatively few examples of clinically important drug-drug interactions at the blood-brain barrier that involve increased drug exposure within the brain. As mentioned previously, alterations in uptake into the brain may not be manifest as a change in systemic pharmacokinetics and may only become apparent when a pharmacodynamic assessment is made . Furthermore, it may not be possible, with therapeutic doses, to achieve sufficiently high concentrations of a co-substrate to allow a drug-drug interaction to take place. For example, a range of antipsychotic, antiemetic and Ca2+ blocking agents failed to produce effective inhibition of p-glycoprotein despite the achievement of suitable concentrations within the systemic circulation . Perhaps more importantly, it should be remembered that clinical and laboratory findings suggest that Mectizan®-associated L. loa encephalopathy is consistent with an embolic process triggered by massive microfilarial death. It may also involve circulating immune complexes or polymorphic inflammatory responses. Moreover, serious or even fatal encephalopathy may develop spontaneously, or following treatment with other microfilaricides such as diethylcarbamazine . It is therefore questionable whether any of the neurological sequelae associated with administration of ivermectin are directly related to the drug and therefore it seems unlikely that any alterations in the pharmacokinetics of ivermectin for whatever reason would result in a more severe adverse reaction.
Geoffrey Edwards was sole author.
Original work referred to by the author (references 32 and 34) was supported by a postgraduate studentship from GlaxoSmithKline Pharmaceuticals to Dr Helen Rawden.
This article is published under license to BioMed Central Ltd. This article is in the Public Domain